The use of probiotics for eczema (atopic dermatitis) is supported by a moderate amount of scientific investigation, though the overall quality and consistency of evidence is limited. Some studies and meta-analyses have suggested that certain probiotic strains, particularly Lactobacillus rhamnosus GG, may help reduce the risk of developing eczema in infants, especially when given to pregnant or breastfeeding mothers. Randomized controlled trials have shown modest benefits in reducing eczema severity or incidence, especially in high-risk populations. However, results are inconsistent, and not all studies have found significant effects. Reviews by organizations such as the World Allergy Organization and Cochrane indicate that while probiotics are generally safe, the evidence for their use in preventing or treating established eczema is weak or inconclusive due to variability in strains, dosages, populations studied, and outcome measures.

Most clinical guidelines do not currently recommend probiotics as a primary treatment for eczema, but some consider them as a supplementary option, particularly in infants at high risk for allergic disease. There is no strong evidence to support their use in adults for eczema. In summary, probiotic use for eczema is backed by some scientific studies with low-to-moderate quality evidence, but findings are not robust or consistent enough for strong clinical recommendations.